Sie sind hier: Skip Navigation LinksKlinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie

AG Genetics of Myeloid Neoplasia Diseases

Myeloid neoplasms (for example, myelodysplastic syndrome [MDS] and acute myeloid leukemia [AML]) are cancers of the hematopoietic system with a wide spectrum of clinical presentations: they occur in young adults or even children, but more frequently affect older persons or patients who have received chemotherapy or radiation treatment for another cancer. While some patients with MDS have a benign clinical course over many years, and some AML patients are cured by chemotherapy or stem cell transplantation, others have aggressive disease and many patients still die of their disease.

Understanding the genetic and epigenetic factors that underlie this heterogeneous presentation has been the focus of our work over the past 10 years. Using modern high-throughput sequencing methods, we comprehensively defined the spectrum and prognostic relevance of driver gene mutations in AML and identified distinct genetic subsets of this disease. These genetic analyses also uncovered that overt myeloid neoplasms such as MDS and AML are often preceded by a 'pre-leukemia' phase where patients still have relatively normal blood counts and no symptoms, while some of their blood cells already carry clonal somatic genetic alterations also found in AML and MDS.

Meanwhile, it has become clear that this phenomenon, called ‚clonal hematopoiesis' (CH), is in fact very common among elderly persons: Among elderly individuals with no hematological disease aged ≥70 years, CH can be identified in over 40%. Importantly, recent studies have shown that mutant blood cell clones in persons with CH associate with inflammatory diseases, including vascular inflammation and atherosclerosis. These recent developments move early clonal alterations of hematopoiesis into the spotlight: they are not only precursor stages of rare types of blood cancer, but in fact represent a very common age-associated phenomenon with direct pathophysiological links to common diseases such myocardial infarction, stroke and autoimmune disease.

Therefore, understanding the genetic mechanisms that drive evolution of myeloid neoplasia from the earliest steps of clonal hematopoiesis to overt myeloid neoplasia, as well as further changes occurring during and after treatment, is at the center of our current translational research projects.

Methodologically, we use state of the art genomics techniques including next-generation sequencing, nanopore sequencing, single-cell analyses, digital droplet PCR and cell-free nucleic acid analyses, in a patient-centered approach. Our work is based on close interactions with our diagnostic laboratory, national and international study groups (e.g. the German MDS study group D-MDS) and our national and international collaborators.

Group leader​Prof. Dr. med. Klaus Metzeler 
Co-worker​​

Our group is relocating from LMU Munich to the University of Leipzig – and we are recruiting! A postdoc position at the interface of translational research and molecular diagnostics is currently available. If you are interested to pursue research projects AND transfer your work into the clinic, please contact Klaus.

Projects for MD theses are also available – please inquire via email (klaus.metzeler@medizin.uni-leipzig.de).

 

References:

 

Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, Konstandin NP, Dufour A, Schneider S, Neusser M, Ksienzyk B, Greif PA, Subklewe M, Faldum A, Bohlander SK, Braess J, Wörmann B, Krug U, Berdel WE, Hiddemann W, Spiekermann K, Metzeler KH.

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.

Leukemia. 2020 Dec;34(12):3161-3172.

 

Grunwald VV, Hentrich M, Schiel X, Dufour A, Schneider S, Neusser M, Subklewe M, Fiegl M, Hiddemann W, Spiekermann K, Rothenberg-Thurley M, Metzeler KH.

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.

Blood Adv. 2019 Sep 24;3(18):2696-2699.

 

Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Haematologica. 2018 Nov;103(11):1853-1861.

 

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Leukemia. 2018 Jul;32(7):1598-1608.

 ​

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Nature. 2016 Dec 15;540(7633):433-437.

 

Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K; AMLCG Study Group.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Blood. 2016 Aug 4;128(5):686-98.: 27288520.​

Liebigstr. 20 (Haus 4) und 22 (Haus 7), Johannisallee 32A (Haus 9)
04103 Leipzig
Telefon (Sekretariat):
0341 - 97 13050
Ambulanz (Haus 9):
0341 - 97 13081
Fax:
0341 - 97 13059
Map